Metabolic imaging of patients’ lymphocytes for personalized assessment of immunotherapy efficiency
Diana V Yuzhakova1, Daria A. Sachkova1, 2, Anna V. Izosimova1, Konstantin S. Yashin1, 3, Varvara V. Dudenkova1, Vadim V. Elagin1, Vladislav I Shcheslavskiy1, 4, Irina S. Shumskaya5, Sergey V. Gamayunov5, Marina V. Shirmanova 1; 1 Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia | ;2 Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, 23 Gagarin Ave., 603950 Nizhny Novgorod, Russia; 3 Department of Neurosurgery, Privolzsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia |; 4 R&D Department, Becker&Hickl GmbH, 7–9 Nunsdorfer Ring, 12277 Berlin, Germany; 5 Nizhny Novgorod Regional Oncology Dispensary, Nizhny Novgorod, Russia.
7
Abstract
One of the key challenges in cancer immunotherapy is the rapid, highly sensitive assessment of immune cell reactivity. Fluorescence lifetime imaging (FLIM) of metabolic coenzymes can be a powerful non-destructive label-free tool to fully characterize the functional status of immune cells. 9In the present study we demonstrated the potential of FLIM to: 1) identify the response of the immune system to the tumor development; 2) predict the individual effectiveness of immunotherapy before treatment and monitor it on in the early treatment stages; 3) test the efficiency of new agents for adoptive cell immunotherapy. This research was funded by the Russian Science Foundation, grant number 23-74-10109.
Speaker
Diana Yuzhakova
Privolzhsky Research Medical University
Russia
Discussion
Ask question
